Financial Performance - Revenue increased by 32.9% from RMB 945.0 million for the year ended December 31, 2024, to RMB 1,255.9 million for the year ended December 31, 2025[4] - Gross profit rose by 20.3% from RMB 361.6 million for the year ended December 31, 2024, to RMB 435.1 million for the year ended December 31, 2025[4] - Adjusted net profit (non-IFRS measure) increased by 9.0% from RMB 84.4 million for the year ended December 31, 2024, to RMB 92.0 million for the year ended December 31, 2025[4] - Loss from continuing operations for the year ended December 31, 2025, was RMB 379.7 million, compared to a profit of RMB 9.0 million for the year ended December 31, 2024, primarily due to changes in the fair value of convertible redeemable preferred shares[4] - Total comprehensive loss for the year ended December 31, 2025, was RMB 379.7 million, compared to a profit of RMB 10.4 million for the year ended December 31, 2024[6] - The company reported a net loss attributable to shareholders of RMB 379,721 thousand for the year ended December 31, 2025, compared to a profit of RMB 10,398 thousand in 2024[7] - Basic loss per share from continuing and discontinued operations was RMB (4.58) for the year ended December 31, 2025, compared to RMB 0.13 in 2024[7] Expenses - Research and development expenses increased from RMB 72.0 million for the year ended December 31, 2024, to RMB 75.6 million for the year ended December 31, 2025[6] - General and administrative expenses slightly increased from RMB 71.6 million for the year ended December 31, 2024, to RMB 72.4 million for the year ended December 31, 2025[6] - Sales and marketing expenses rose from RMB 158.5 million for the year ended December 31, 2024, to RMB 213.4 million for the year ended December 31, 2025[6] - The company incurred a total procurement cost of RMB 756,466,000, which increased from RMB 513,994,000 in the previous year[17] - Total sales and marketing expenses increased by 34.6% from RMB 158.5 million in 2024 to RMB 213.4 million in 2025, driven by higher promotional spending and an increase in sales personnel[73] Assets and Liabilities - Non-current assets totaled RMB 31,362 thousand in 2025, a decrease from RMB 107,505 thousand in 2024[8] - Current assets decreased to RMB 1,160,587 thousand in 2025 from RMB 581,724 thousand in 2024[8] - Current liabilities amounted to RMB 182,502 thousand in 2025, down from RMB 1,898,642 thousand in 2024[9] - The company's net assets were RMB 1,002,222 thousand in 2025, compared to a net liability of RMB (1,218,546) thousand in 2024[9] - As of December 31, 2025, total liabilities amounted to RMB 73,690,000, a significant increase from RMB 34,503,000 in 2024, reflecting a growth of approximately 113%[32] Revenue Breakdown - Revenue from health-related services reached RMB 926,338,000, up 50% from RMB 616,927,000 in the previous year[16] - Insurance technology service revenue was RMB 221,354,000, an increase of 17.6% compared to RMB 188,280,000 in 2024[16] - Health-related services accounted for 73.7% of total revenue in 2025, up from 65.3% in 2024, highlighting its role as a core growth engine[62] Shareholder Information - The company did not declare or recommend any dividends to ordinary shareholders for the years ended December 31, 2025, and 2024[22] - The company has a total of 5,000,000,000 authorized shares, with 800,683,566 shares issued and outstanding as of December 31, 2024, and 206,374,209 shares issued and outstanding as of December 31, 2025[34][35] - The public float of the company is 37.94%, which complies with the minimum requirement of 25% as per the listing rules[122] Corporate Governance - The board expresses gratitude to customers, business partners, employees, and shareholders for their continued support[132] - The company is committed to good corporate governance practices and has adhered to the corporate governance code as outlined in the listing rules[123] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2025, and recommended approval to the board[125] Future Plans and Projections - The company aims to build a leading integrated health service platform in China, creating a sustainable health service ecosystem for corporate clients and partners[49] - The company plans to launch a clinical decision support AI system by March 2026, enhancing medical decision-making capabilities for physicians[55] - The company plans to utilize the net proceeds from the global offering for operational funding and other general corporate purposes, with a reasonable estimate of usage based on the latest information available[116][114] Digital Marketing and Research - The digital marketing segment achieved a growth rate of 52.1% in 2025 due to the optimization of the health content ecosystem[46] - The company focuses on real-world research project design and in-depth analysis of clinical trial data as part of its digital medical research support services[46] - The company has accumulated over 1.2 million health content creations, with educational content views increasing by 238.1% year-on-year[50] Employee Information - As of December 31, 2025, the company has 213 employees, with employee costs (including director remuneration and share-based payment expenses) amounting to approximately RMB 160.5 million[117] - The company has not encountered any significant labor disputes or difficulties in hiring or retaining employees as of the announcement date[119]
轻松健康(02661) - 2025 - 年度业绩